Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 7/20 | 0.56 |
| ▸ | CA1 | P00915 | 7/20 | 0.56 |
| ▸ | CA2 | P00918 | 7/20 | 0.56 |
| ▸ | CA9 | Q16790 | 7/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | ITK | Q08881 | 2/20 | 0.45 |
| ▸ | SUCNR1 | Q9BXA5 | 5/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20100194 | 1.00 | CA12 (0.56) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL21160682 | 0.95 | CA12 (0.54) | CA12CA1CA2CA9EGFR | |
| SCHEMBL8705236 | 0.92 | CA12 (0.53) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL17687916 | 0.89 | CA12 (0.50) | CA12CA1CA2CA9EGFR | |
| SCHEMBL24142775 | 0.87 | CA12 (0.56) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL17687929 | 0.85 | CA12 (0.49) | CA12CA1CA2CA9EGFR | |
| SCHEMBL463829 | 0.83 | CA12 (0.61) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL30448576 | 0.83 | CA12 (0.61) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL25718690 | 0.83 | CA12 (0.61) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL31192622 | 0.83 | CA12 (0.55) | CA12CA1CA2CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124419-A1 | SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-04-18 | — | — | US | disclosed |
| EP-4288416-A2 | SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF | The Regents Of The University Of Michigan (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-4144738-A1 | COELENTERAZINE ANALOGUES TETHERED TO ENERGY ACCEPTORS | Promega Corporation (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2022169834-A2 | SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-08-11 | — | — | WO | disclosed |
| EP-3535270-B1 | COELENTERAZINE ANALOGUES TETHERED TO ENERGY ACCEPTORS | PROMEGA CORP (US) | 2022-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124419-A1 | SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF | HSPA5, HSPA2, PSMG3 | CA12 2563/4885CA1 3906/4885CA2 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.